Mindfulness-based cognitive therapy (MBCT) is cost-effective compared to a wait-list control for persistent pain in women treated for primary breast cancer-Results from a randomized controlled trial

2017 ◽  
Vol 26 (12) ◽  
pp. 2208-2214 ◽  
Author(s):  
M. Johannsen ◽  
J. Sørensen ◽  
M. O'Connor ◽  
A.B. Jensen ◽  
R. Zachariae
Keyword(s):  
Breast Cancer ◽  
Randomized Controlled Trial ◽  
Cognitive Therapy ◽  
Primary Breast Cancer ◽  
Controlled Trial ◽  
Cost Effective ◽  
Persistent Pain ◽  
Wait List ◽  
Wait List Control ◽  
Randomized Controlled

scholarly journals Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition

PLoS ONE ◽  
2016 ◽  
Vol 11 (12) ◽  
pp. e0166601 ◽  
Author(s):  
Noud van Helmond ◽  
Monique A. Steegers ◽  
Gertie P. Filippini-de Moor ◽  
Kris C. Vissers ◽  
Oliver H. Wilder-Smith
Keyword(s):  
Breast Cancer ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Persistent Pain ◽  
Cancer Surgery ◽  
Breast Cancer Surgery ◽  
Randomized Controlled ◽  
Prospective Randomized Controlled Trial ◽  
Cox 2

Meaning and Purpose (MaP) therapy II: Feasibility and acceptability from a pilot study in advanced cancer

2019 ◽  
Vol 17 (1) ◽  
pp. 21-28 ◽  
Author(s):  
David W. Kissane ◽  
Carrie Lethborg ◽  
Joanne Brooker ◽  
Courtney Hempton ◽  
Sue Burney ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Pilot Study ◽  
Posttraumatic Growth ◽  
Advanced Cancer ◽  
Controlled Trial ◽  
Effect Sizes ◽  
Wait List ◽  
Wait List Control ◽  
Randomized Controlled ◽  
Meaning And Purpose

AbstractObjectiveMeaning and Purpose (MaP) therapy aims to enhance meaning-based coping through a life review that focuses on the value and worth of the person, key relationships, sources of fulfillment, roles, and future priorities in living life out fully. We sought to test the feasibility and acceptability of a six-session model of MaP therapy against a wait-list control cohort in a pilot study seeking effect sizes on measures of adaptation.MethodWe randomized patients with advanced cancer to MaP therapy or wait-list control, with measures administered at baseline and after 6–8 weeks. Wait-list patients could then crossover to receive therapy, with further measures collected postintervention. Adherence to the manualized model was sustained through weekly supervision and fidelity coding of recorded sessions. We used generalized estimating equations to control for baseline and any correlation of data.ResultFrom 134 eligible participants, 57 (43%) consented, and 40 of 45 (89%) offered therapy completed 6 sessions. Key barriers to consenting patients were poor health (15 refusers and 4 withdrawals) and death intervened in 6 participants. MaP therapy generated adequate effect sizes in posttraumatic growth (new possibilities, appreciation of life, and personal strength) and life attitudes (choices and goal seeking) to permit calculation of power for a formal randomized, controlled trial.Significance of resultsDelivery of this model of existentially oriented therapy is feasible and acceptable to patients. A properly powered randomized controlled trial is justified to examine the efficacy of this intervention.

scholarly journals Testing a mindfulness meditation mobile app for the treatment of sleep-related symptoms in adults with sleep disturbance: A randomized controlled trial

PLoS ONE ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. e0244717
Author(s):  
Jennifer L. Huberty ◽  
Jeni Green ◽  
Megan E. Puzia ◽  
Linda Larkey ◽  
Breanne Laird ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Sleep Disturbance ◽  
Daytime Sleepiness ◽  
Controlled Trial ◽  
Intervention Group ◽  
Mobile App ◽  
Wait List ◽  
Wait List Control ◽  
Randomized Controlled ◽  
Sleep Arousal

The objective of this randomized controlled trial was to test whether a commercially available, mindfulness meditation mobile app, (i.e., Calm app), was effective in reducing fatigue (primary outcome), pre-sleep arousal, and daytime sleepiness (secondary outcomes) in adults with sleep disturbance (Insomnia Severity Index Score >10) as compared to a wait-list control group. Associations between the use of the Calm app (i.e., adherence to the intervention) and changes in sleep quality was also explored in the intervention group only. Adults with sleep disturbance were recruited (N = 640). Eligible and consenting participants (N = 263) were randomly assigned to the intervention (n = 124) or a wait-list control (n = 139) group. Intervention participants were asked to meditate using the Calm app ≥10 minutes/day for eight weeks. Fatigue, daytime sleepiness, and pre-sleep arousal were assessed at baseline, mid- (4-weeks) and post-intervention (8-weeks) in both groups, whereas sleep quality was evaluated only in the intervention group. Findings from intent-to-treat analyses suggest the use of the Calm app for eight weeks significantly decreased daytime fatigue (p = .018) as well as daytime sleepiness (p = .003) and cognitive (p = .005) and somatic (p < .001) pre-sleep arousal as compared to the wait-list control group. Within the intervention group, use of the Calm app was associated with improvements in sleep quality (p < .001). This randomized controlled trial demonstrates that the Calm app can be used to treat fatigue, daytime sleepiness, and pre-sleep arousal in adults with sleep disturbance. Given that the Calm app is affordable and widely accessible, these data have implications for community level dissemination of a mobile app to improve sleep-related symptoms associated with sleep disturbance. Trial registration: ClinicalTrials.gov NCT04045275.

Sign in / Sign up

Export Citation Format

Share Document